Wide Ranks

INCY

Incyte Corporation

75.45

Top Statistics
Market Cap 14 B Forward PE 12.51 Revenue Growth 23.80 %
Current Ratio 1.87 Trailing PE 838.33 Earnings Growth -28.90 %
Profit Margins 0.80 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 158.99 Enterprise / Revenue 3.14 Price To Sales Trailing12 Months 3.57
Profitability
Profit Margins 0.80 % Operating Margins 14.96 %
Balance Sheet
Total Cash 1 B Total Cash Per Share 9.21 Total Debt 36 M
Total Debt To Equity 1.15 Current Ratio 1.87 Book Value Per Share 16.45
All Measures
Short Ratio 353.00 % Message Board Id finmb_332954 Shares Short Prior Month 7 M
Return On Equity 0.0080 City Wilmington Uuid 72960770-e83b-3ec3-92c6-dbd8ced339a4
Previous Close 74.80 First Trade Date Epoch Utc 752 M Book Value 16.45
Beta 0.7100 Total Debt 36 M Volume 1 M
Price To Book 4.59 Last Split Date 967 M Fifty Two Week Low 50.35
Total Cash Per Share 9.21 Total Revenue 4 B Shares Short Previous Month Date 1 B
Target Median Price 77.00 Max Age 86400 Recommendation Mean 2.19
Sand P52 Week Change 0.3133 Operating Margins 14.96 % Target Mean Price 78.31
Net Income To Common 32 M Short Percent Of Float 0.0646 Implied Shares Outstanding 192 M
Trailing Peg Ratio 63.70 % Last Fiscal Year End 1 B Average Daily Volume10 Day 3 M
Average Volume10days 3 M Total Cash 1 B Next Fiscal Year End 1 B
Revenue Per Share 18.97 Held Percent Insiders 0.0204 Ebitda Margins 1.98 %
Trailing PE 838.33 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 74.80 Target Low Price 52.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 70.41 Open 75.00 Free Cashflow 482 M
State DE Dividend Yield 0.00 % Return On Assets -0.0012
Time Zone Short Name EST Trailing Eps 0.0900 Day Low 74.80
Address1 1801 Augustine Cut-Off Shares Outstanding 192 M Price Hint 2
Target High Price 97.00 Website https://www.incyte.com 52 Week Change 0.3885
Average Volume 2 M Earnings Quarterly Growth -37.80 % Forward Eps 6.14
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 168.70 %
Last Split Factor 2:1 Regular Market Day High 76.14 Is_sp_500 True
Profit Margins 0.80 % Debt To Equity 1.15 Fifty Two Week High 83.95
Day High 76.14 Shares Short 6 M Regular Market Open 75.00
Industry Key biotechnology Earnings Growth -28.90 % Enterprise To Revenue 3.14
Revenue Growth 23.80 % Shares Percent Shares Out 0.0363 Operating Cashflow 101 M
Currency USD Time Zone Full Name America/New_York Market Cap 14 B
Is_nasdaq_100 False Zip 19803 Quote Type EQUITY
Industry Biotechnology Long Name Incyte Corporation Regular Market Day Low 74.80
Held Percent Institutions 0.9784 Current Price 75.45 Enterprise To Ebitda 158.99
Financial Currency USD Current Ratio 1.87 Gross Margins 29.33 %
Industry Disp Biotechnology Number Of Analyst Opinions 23 Country United States
Float Shares 160 M Two Hundred Day Average 62.37 Ir Website http://investor.incyte.com/phoenix.zhtml?c=69764&p=irol-irhome
Enterprise Value 12 B Price To Sales Trailing12 Months 3.57 Forward PE 12.51
Regular Market Volume 1 M Ebitda 80 M Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally.

The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.

Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors.

The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460.

It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib.

The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers.

The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003.

Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.